Sharp increases in infectious syphilis and congenital syphilis are prompting calls for improved surveillance, prevention and testing strategies, and the destigmatization of sexually transmitted infections.
Two new antiretrovirals have been approved by the US Food and Drug Administration since the US Preventive Services Task Force s last report, which now includes new options.